Seeking efficiency in executive compensation benchmarking?

Unlock Efficiency in Executive Compensation Benchmarking with CompAnalyst Executive

CompAnalyst Executive

The charts on this page feature a breakdown of the total annual pay for the top executives at VIRACTA THERAPEUTICS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. VIRACTA THERAPEUTICS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. VIRACTA THERAPEUTICS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Lisa Rojkjaer M.D.
Chief Medical Officer
Total Cash $633,192 Equity $333,000 Other $13,866 Total Compensation $980,058
Ivor Royston M.D.
Former President and Chief Executive Officer
Total Cash $591,923 Equity $915,750 Other $2,035,734 Total Compensation $3,543,407
Daniel Chevallard
Chief Financial Officer, Chief Operating Officer, Treasurer, Secretary
Total Cash $633,945 Equity $432,900 Other $13,964 Total Compensation $1,080,809
Mark Rothera
President and Chief Executive Officer
Total Cash $357,614 Equity $5,355,625 Other $7,418 Total Compensation $5,720,657
For its 2021 fiscal year, VIRACTA THERAPEUTICS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Barry J. Simon, M.D. Total Cash $570,862
David C. Stump, M.D. Total Cash $8,333
Flavia Borellini Total Cash $542,894
Gur Roshwalb, M.D. Total Cash $552,847
Henry Ward Wolff Total Cash $10,000
Homer L. Pearce, Ph.D. Total Cash $9,167
James W. Young, Ph.D. Total Cash $10,000
Jane F. Barlow, M.D., M.P.H., M.B.A. Total Cash $545,278
Michael Huang, M.S., M.B.A. Total Cash $561,200
Nicole Onetto, M.D. Total Cash $569,584
Roger J. Pomerantz, M.D. Total Cash $1,731,797
Sam Murphy, Ph.D. Total Cash $557,954
Stephen Rubino, Ph.D., M.B.A. Total Cash $566,499
Steve Carchedi Total Cash $10,833
Steve Ketchum, Ph.D. Total Cash $7,500
Thomas E. Darcy, CPA Total Cash $574,299

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.